Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page
- ChecktodayChange DetectedRevision metadata updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedFooter now shows Revision: v3.3.3. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed.SummaryDifference0.1%

- Check50 days agoChange DetectedFooter revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check58 days agoChange DetectedThe notice about a lapse in government funding and related operating-status updates has been removed from the page.SummaryDifference0.3%

- Check72 days agoChange DetectedThe update appears to show only minor layout adjustments with no changes to the core study content, such as design, endpoints, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check100 days agoChange DetectedCore content updated with new government-status notice and version 3.2.0; a specific resource entry (Small cell lung carcinoma) was deleted (v3.1.0).SummaryDifference4%

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.